クイックコネクト

CPHI Japan 2025

CPHI Japan 2025

Join us to learn how we can streamline and optimize your API sourcing

Meet us at Suite 5N-12

April 9 - 11, 2025
Tokyo Big Sight, East Hall 4, 5 & 6, Tokyo, Japan
Schedule a meeting
Verified

Our Team at CPHI Japan 2025

About Dr.Reddy’s API Business

We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 150+ active pharmaceutical ingredients, which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom.

Dr. Reddy's API  business operates in a number of global markets, including the United States of America, Latin America, Europe, India, Russia, and other CIS nations.

  • 250+ APIs

  • 8 Manufacturing sites

  • 1950 drug master files across global markets.

  • Over 325 ANDAs

  • More than 1000 patents field, and more than 70 own patents granted

  • Experience with complex APIs and formulations supporting early market entries.

  • Preferred pharma API supplier for pharma companies in more than 80 countries.

Sustainability

Dr. Reddy's is among the top sustainable pharmaceutical companies globally. We are listed in the sustainability yearbook of S&P 2022 for the second year in a row and the Bloomberg Gender-Equality Index (GEI) for the fifth consecutive year. In addition, we were ranked ninth in the Dow Jones Sustainability Index (DJSI) 2021 among the most sustainable pharmaceutical companies in the world. In our sustainability journey, these accolades are humbling and demonstrate that we're on the right track. These awards recognize our consistent performance in the environment, social, and governance (ESG) framework. Sustainability and ESG are becoming increasingly important topics for all stakeholders, so we will strive to maintain visibility in these areas.

What we achieved in the past year:

 
 

Our Achievement (awards)

Our Plants

About CPHI Japan 2025

CPHI Japan 2025 is a leading event in the pharmaceutical industry, set to take place from April 9 to 11, 2025, at Tokyo Big Sight in Tokyo, Japan. Bringing together over 26,000 industry professionals and 730+ exhibitors from 60 countries, the event serves as a key platform for networking, collaboration, and knowledge-sharing. With a strong focus on innovation and business growth, CPHI Japan covers the entire pharmaceutical supply chain, offering insights into the latest trends, regulatory updates, and technological advancements shaping the industry.

Networking is at the heart of CPHI events, offering professionals a chance to build meaningful partnerships and strengthen existing collaborations. Dedicated networking lounges, informal meetups, and digital matchmaking tools help attendees connect with potential business partners, service providers, and key decision-makers. The event creates opportunities to explore new markets, establish supply chain relationships, and stay informed about the latest innovations driving the pharmaceutical sector forward. Join us to discover our innovative solutions, and learn how we can contribute to the advancement of the pharmaceutical sector together

Company

 

Contact Us

 

Follow Us on

Dr. Reddy’s Laboratories, 8-2-337,
Banjara Hills Rd Number 3,
SBI Executive Enclave, Green Valley,
Banjara Hills, Hyderabad,
Telangana 500034
Phone: 040 4900 2222

© 2025 Dr. Reddy’s Laboratories Ltd. All rights reserved.

免責事項

製品またはサービスへの参照を含むこのカタログの情報は、販売の申し出を構成するものではなく、販売の申し出を表すものとして解釈されるものではありません。有効な特許で保護された製品は、商用目的で提供または提供されません。ただし、そのような規制上の免除が存在する場合は、規制当局への提出を目的として、そのような製品の調査数量が提供される場合があります。購入者は、それぞれの市場の特許シナリオを独自に評価する必要があり、すべての特許関連の責任を負うものとします。インドで有効な特許に基づいて保護されている製品は、商用利用はできませんが、セクション 107A の目的には利用できます。

製品またはサービスへの参照を含むこのカタログの情報は、販売の申し出を構成するものではなく、販売の申し出を表すものとして解釈されるものではありません。有効な特許で保護された製品は、商用目的で提供または提供されません。ただし、そのような規制上の免除が存在する場合は、規制当局への提出を目的として、そのような製品の調査数量が提供される場合があります。購入者は、それぞれの市場の特許シナリオを独自に評価する必要があり、すべての特許関連の責任を負うものとします。インドで有効な特許に基づいて保護されている製品は、商用利用はできませんが、セクション 107A の目的には利用できます。

X

Our experts are ready to resolve
your API sourcing bottlenecks

Meet us at booth: 5N-12

April 9 - 11, 2025

Tokyo Big Sight, East Hall 4, 5 & 6, Tokyo, Japan

Join us at CPHI Japan